Paragraph IV and biosimilar notice response, with the clocks set and a cited first-response pack the same day
Every generic or biosimilar challenge gets its clocks set and a cited response pack the same day, with weeks left to decide.
See one case, screen by screen ↓A Paragraph IV notice letter starts the clock the day the courier delivers it. Sue inside 45 days and FDA approval of the ANDA is stayed for 30 months; miss the window and the stay is gone. Before anyone can advise the chief patent counsel, someone has to confirm the receipt, check the notice against 21 CFR 314.95, docket the dates, chart every contention in the detailed statement against the listed claims, issue the litigation hold and brief outside counsel.
Most of that is reading, and most of what is read has been argued before. The same obviousness combination, the same inducement argument on the label, the same IPR grounds come back filer after filer — answered in an expert report, a claim-construction order or a file history that sits in another matter. Finding the one argument that is genuinely new, such as prior art the examiner never saw, is the work that matters, and it is the work that gets the least time.
Estimated split of the roughly 12 days from receipt to a first-response pack, by hand and with the solution. Counsel review and the suit decision come after, either way.
Six specialist agents read the notice, keep every clock, map each argument to what we argued before and draft the response pack; counsel reviews and the chief patent counsel decides.
Wednesday, October 7. A Paragraph IV notice from Juniper Generics is signed for at 08:41. Brightwell Pharma’s, delivered two days earlier on the same Corventa patents, is ready for a decision. Here is the morning, screen by screen, in the working solution.
Dana opens the clock wall: 6 statutory clocks running across 5 matters, 1 notice arrived today. Each ring shows the window left — 11 days until Tamsin sends its biosimilar application, 43 to sue Brightwell, 45 to sue Juniper, 87 to the IPR response on the ’418. Needs you lists the new Juniper notice first.
Clock Keeper: “Juniper: 45 days to Nov 21 — a Saturday, so file by Nov 20.”
Lena Ortiz, the litigation paralegal, has confirmed the 08:41 courier receipt. The agents then work in view: the Notice Reader checks the letter, the Clock Keeper sets the suit window, the Contention Mapper reads the 31-page detailed statement, and the Prior Positions Finder searches 2,318 records of past cases and file histories.
“Counsel review — waiting for Dana Okafor. Matrix ready · suit decision due by Nov 20.”
Sent after FDA’s acknowledgment letter and within 20 days of it. ANDA 220455 for vandorixant tablets, 10 mg. The ’772 and ’418 under Paragraph IV, the ’207 under Paragraph III. A detailed statement on pages 9–27, an offer of confidential access, the courier proof of delivery. Each check links to the page it rests on.
“A notice sent before FDA’s acknowledgment, or without a detailed statement, would not start the clock.”
Day 45 is Saturday, Nov 21, so the target is Friday, Nov 20. A timely suit stays approval to Apr 7, 2029, and Juniper’s Paragraph III certification separately holds it behind the ’207 until Mar 15, 2033. The litigation hold has an internal target too: day 4 is a Sunday, so Friday, Oct 9.
Nine contentions on eight claims, one cell per claim and ground. Seven are already answered: the Rao 2012 obviousness combination by the Voss reply report, the eGFR inducement argument by the summary-judgment opinion in the Ivel case, the ’611 grounds by the instituted IPR. Two are new — a release of 76% at 12 hours against claim 9’s 80%, and written description of the 10 mg tablet.
“Juniper notice mapped — 2 of 9 arguments are new.”
In Brightwell’s statement, four of eleven contentions are new. The one to watch: claims 1 and 3 of the ’772 are said to be anticipated by the Kessler abstract from the November 2013 Heart Failure Congress. Beside what Brightwell says sits what we said before — the abstract is in no disclosure statement for the ’772, neither Halvard nor Ivel relied on it, and it says nothing about eGFR or a beta-blocker.
Assessment for counsel: “Claims 1 and 3 are at risk; claims 7 and 11 add steps the abstract does not disclose.”
The briefing to Whitcombe & Rowe says what is new, what we already have and what we ask, with the first pass budgeted at 60 hours. The litigation hold goes to custodians in formulation development, regulatory affairs, clinical development for studies VND-201 and VND-301, medical affairs, the Corventa brand team and IT — with what to keep and a date to reply by.
Nothing leaves until its named signer approves: Dana for the hold, Sam Patel for the briefing.
Recommendation: sue Brightwell on the ’772 and ’418 in the District of Delaware before Nov 19, 2026, keeping the stay to Apr 5, 2029. Assert ’772 claims 1, 3, 7 and 11 and ’418 claims 1, 4, 9 and 14. Venue facts, and what is still open before filing: confidential access to the ANDA and outside counsel’s validity read on the abstract.
Omar sees 43 days left, 4 of 11 arguments new and 5 assessments accepted by counsel. He chooses between suing in Delaware, in Delaware and New Jersey, on the ’418 only, or not suing — each with its consequence stated. The note to outside counsel asks for the validity read on the Kessler abstract before the complaint is final.
“The stay is lost after Thu, Nov 19; Brightwell may then seek a declaratory judgment.”
The decision is recorded in the audit trail with his name. Whitcombe & Rowe are instructed to file by Nov 19, the memo inputs are attached to the decision, Priya Raman’s exclusivity map is updated and Lena Ortiz has the docket — with 43 days still on the clock.
“Decision signed · Whitcombe & Rowe instructed to file by Nov 19 · exclusivity map updated.”
The same two notices, seen by the five people who handle them — what the first weeks looked like, and what they look like now.
Six specialist agents read the notice, keep every clock, map each argument to what we argued before and draft the response pack; counsel reviews and the chief patent counsel decides.
Reads each notice letter, biosimilar notice and detailed statement; extracts the application, product, strength, each listed patent with its expiry and certification, and the courier receipt; runs the 21 CFR 314.95 checks.
Computes every statutory date — the 45-day suit window, the 30-month stay, patent-dance steps, IPR responses — applies weekend and court-holiday rules, writes them to the docket and sets the alerts.
Splits the detailed statement into contentions and links each to the claims it attacks and its ground — non-infringement, inducement, anticipation, obviousness, §112, double patenting.
Matches each contention to what we argued before — orders, expert reports, IPR papers, file histories — and labels it answered before, answered by the record, or new, with what would test a new one and who should look.
Drafts the litigation-hold notice, the outside-counsel briefing and the suit-decision memo inputs from the matter, the matrix and the clocks.
Runs the biosimilar patent dance for each applicant — application, our list, their statement, our response, negotiation and suit — with the clock for each step, and routes each list and response to counsel.
Signs the suit decision. The agents propose; a named person decides.
Counsel can ask in plain words — or tell it what to change. Answers cite the notice, the order or the file history they rest on.
What is new in Brightwell’s arguments?
Four of Brightwell’s 11 contentions are new: the osmotic-pump tablet with no hydrophilic matrix, HPMC at only 12%, not more than 70% release at 12 hours, and the Kessler 2013 congress abstract. The abstract is the one to watch: it was never before the examiner, and it says nothing about eGFR or beta-blockers — so claims 7 and 11 stand clear of it.
When must we sue Juniper?
By Friday, Nov 20, 2026. Juniper’s notice was delivered on Oct 7 at 08:41, so day 45 is Saturday, Nov 21. Whether a weekend extends the statutory window is not settled, so the target is the business day before. A timely suit stays approval to Apr 7, 2029.
How serious is the Kessler abstract?
It is the one genuinely new attack. It describes 10 mg once daily in 48 patients with HFrEF, was published a year before our Nov 4, 2014 priority date, and was never cited to the examiner or raised by Halvard or Ivel. Exposure: ’772 claims 1 and 3. Not exposed: claims 7 and 11. Next step: Whitcombe & Rowe’s validity read before the complaint is final.
Alert me 10 days before every suit deadline
Done — a new rule: alert 10 days before every 45-day suit deadline, to you and Omar Haddad. Brightwell’s alert is Nov 9 and Juniper’s Nov 10. You can see it in Settings, under the rules the agents follow.
13 screens from the working solution, on its sample data. Pick one to see it large.
How clocks are counted, who is alerted and who signs are settings. Every change is recorded in the audit trail.
| Setting | Default | Choose from |
|---|---|---|
| Alert before a deadline | 30 · 14 · 7 · 3 · 1 days | 60 · 30 · 14 · 10 · 7 · 3 · 1 days |
| Escalate an unacknowledged alert after 24 hours | Omar Haddad | Omar Haddad · Dana Okafor · Lena Ortiz · Sam Patel · Priya Raman |
| What starts a 45-day suit window | Courier receipt, confirmed by a paralegal | Courier receipt · Date on the letter · Scan time |
| When day 45 falls on a weekend or court holiday | Warn and set the target to the business day before | Business day before · Roll to the next business day |
| Who signs suit decisions | Omar Haddad | Omar Haddad · Dana Okafor · Lena Ortiz · Sam Patel · Priya Raman |
| Who signs litigation holds | Dana Okafor | Omar Haddad · Dana Okafor · Lena Ortiz · Sam Patel · Priya Raman |
| Who releases outside-counsel briefings | Sam Patel | Omar Haddad · Dana Okafor · Lena Ortiz · Sam Patel · Priya Raman |
| Who sees confidential-access material | Outside counsel + Dana Okafor | Outside counsel + one named lawyer · Outside counsel only |
Every figure is labelled: a target the solution is built to, an estimate, a typical published result, or a proven one.
“demo” = seen in the working solution, on its sample matters · “target” = the design goal, measured in the live solution · “estimated” = our estimate · “typical” = published figures (AIPLA litigation-cost survey) · Statutory periods: 21 USC 355(j) (45-day suit window, 30-month stay), 21 CFR 314.95, 42 USC 262(l). People, companies, products and patents named on this page are characters in the working solution.
A working tool for the in-house patent litigation team that takes a Paragraph IV notice letter or biosimilar application from the courier receipt to a signed suit decision. Agents check the notice, docket the clocks, map each contention to the claim it attacks and to what you argued before, and draft the litigation hold, the outside-counsel briefing and the decision memo inputs.
From the courier receipt, once a paralegal confirms it. The Clock Keeper counts 45 days under 21 USC 355(j)(5)(B)(iii), applies the weekend and court-holiday rule you set, and writes the suit date, the 30-month stay date and the alerts to your docket.
The Prior Positions Finder searches your litigation record and file histories for the same argument, reference or fact. Each contention is labelled answered before (with the order, brief or report), answered by the record (with the file history or specification) or new — with what would test it and who should look.
Yes. The Notice Reader runs the 21 CFR 314.95 checks — sent after FDA’s acknowledgment and within 20 days of it, the application and product, every listed patent, a detailed statement, an offer of confidential access, the receipt proof. It flags a defective notice; it never fixes one.
Yes. The Dance Tracker follows the 42 USC 262(l) steps for each applicant — application, our patent list, their statement, our response, negotiation and suit — each with its clock, and routes every list and response to counsel for approval.
Every draft is stamped privileged and confidential on every page, and the agents never send anything outside the company. ANDA material received under confidential access, and 262(l)(1) application material, is visible to outside counsel and one named in-house lawyer only.
Yes. The agents give assessments, never legal conclusions. Nothing is sent without a named person’s sign-off, and the suit decision is signed by the Chief Patent Counsel and recorded in the audit trail.
The Agentic Solution Engine builds and deploys it from your requirements and documents — your patent estate, past litigation record, docketing rules and templates — and it goes live once every quality gate has passed. We will walk you through it on one of your own past notices first.
Every patent, court and settlement change becomes a decided, cited generic entry date for each market within hours.
1-min filmThird-Party ContractsEvery contract on their paper redlined against your playbook and back in under two days.
1-min filmAlliance ObligationsEvery licence and collaboration becomes a live register of obligations, with each milestone caught within a day of its trigger.
1-min filmWe’ll run the workbench on one of your own past Paragraph IV notices and its detailed statement.